LEAP-015
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
- NCT04662710 ↗
- Completed
- Merck Sharp & Dohme LLC
- Deep
We haven't built an HCP commentary report on LEAP-015 (lenvatinib plus pembrolizumab in first-line advanced/metastatic gastroesophageal adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LEAP-015 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 22 | |
| YouTube | 2 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Advanced/Metastatic Gastroesophageal Adenocarcinoma
- Interventions
- Pembrolizumab; Lenvatinib; Oxaliplatin; Capecitabine; Leucovorin (or Levoleucovorin); 5-FU
- Arms
- Lenvatinib + Pembrolizumab + Chemotherapy · Experimental
- Chemotherapy · Experimental
- Enrollment
- 895
- Primary outcomes
- Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)
- Part 1: Number of Participants With Adverse Events (AEs)
- Part 1: Number of Participants Who Discontinued Study Treatment Due to an AE
- Part 2: Overall Survival (OS) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1
- Part 2: OS in All Participants
- Part 2: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With PD-L1 CPS ≥1
- Part 2: PFS Per RECIST 1.1 as Assessed by BICR in All Participants
- Sponsor
- Merck Sharp & Dohme LLC with Eisai Inc.
- Start
- Dec 30, 2020
- Primary completion
- Oct 29, 2024
- Results posted
- Yes
- Registry record
- NCT04662710 · updated Apr 28, 2026
Publications
linked from the registry- Shitara K, Lorenzen S, Li J, Bai Y, Fernandez MG, Aguilar M, Shoji H, Reyes-Cosmelli F, Pena YR, Corrales L, Wyrwicz L, Eyzaguirre DA, Pan Y, Ryu MH, Cohen DJ, Wainberg ZA, Ku G, Tabernero J, Van Cutsem E, Qin SK, Oh DY, Xu J, Liang LW, Bordia S, Bhagia P, Rha SY; LEAP-015 Investigators. Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study. J Clin Oncol. 2025 Aug;43(22):2502-2514. doi: 10.1200/JCO-25-00748. Epub 2025 May 31. PubMed 40448579